AU2001278734A1 - Method of extensive culture of antigen-specific cytotoxic t cells - Google Patents

Method of extensive culture of antigen-specific cytotoxic t cells

Info

Publication number
AU2001278734A1
AU2001278734A1 AU2001278734A AU7873401A AU2001278734A1 AU 2001278734 A1 AU2001278734 A1 AU 2001278734A1 AU 2001278734 A AU2001278734 A AU 2001278734A AU 7873401 A AU7873401 A AU 7873401A AU 2001278734 A1 AU2001278734 A1 AU 2001278734A1
Authority
AU
Australia
Prior art keywords
antigen
cells
specific cytotoxic
extensive culture
extensive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278734A
Inventor
Mitsuko Ideno
Ikunoshin Kato
Hiroaki Sagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio Inc
Original Assignee
Takara Shuzo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Shuzo Co Ltd filed Critical Takara Shuzo Co Ltd
Publication of AU2001278734A1 publication Critical patent/AU2001278734A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
AU2001278734A 2000-08-16 2001-08-15 Method of extensive culture of antigen-specific cytotoxic t cells Abandoned AU2001278734A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000247072 2000-08-16
JP2000-247072 2000-08-16
PCT/JP2001/007032 WO2002014481A1 (en) 2000-08-16 2001-08-15 Method of extensive culture of antigen-specific cytotoxic t cells

Publications (1)

Publication Number Publication Date
AU2001278734A1 true AU2001278734A1 (en) 2002-02-25

Family

ID=18737246

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278734A Abandoned AU2001278734A1 (en) 2000-08-16 2001-08-15 Method of extensive culture of antigen-specific cytotoxic t cells

Country Status (8)

Country Link
US (2) US7816134B2 (en)
EP (1) EP1312670A4 (en)
JP (1) JP4231688B2 (en)
KR (1) KR100715926B1 (en)
CN (1) CN1222612C (en)
AU (1) AU2001278734A1 (en)
TW (1) TWI235764B (en)
WO (1) WO2002014481A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816134B2 (en) * 2000-08-16 2010-10-19 Takara Bio Inc. Method of extensive culture of antigen-specific cytotoxic T cells
AU2003221073B2 (en) 2002-03-25 2008-08-21 Takara Bio Inc. Process for producing cytotoxic lymphocyte
DE602004025591D1 (en) 2003-08-22 2010-04-01 Takara Bio Inc METHOD FOR PRODUCING CYTOTOXIC LYMPHOCYTES
CA2617219A1 (en) * 2005-07-29 2007-02-01 Suntory Limited Compositions comprising fucoidan or a fucoidan hydrolysate and an immuno-stimulating material
WO2007020880A1 (en) 2005-08-17 2007-02-22 Takara Bio Inc. Method of producing lymphocytes
US20100068192A1 (en) * 2005-09-30 2010-03-18 Takara Bio Inc. Method for Production of T Cell Population
WO2007142300A1 (en) 2006-06-09 2007-12-13 Takara Bio Inc. Method of producing lymphocytes
KR100896747B1 (en) 2007-05-30 2009-05-11 동아대학교 산학협력단 Composite for Inducing Maturation of Dendritic Cell Containing Fucoidan or its Homologous
KR100947821B1 (en) 2008-01-09 2010-03-15 차의과학대학교 산학협력단 Method for the differentiation of mesenchymal stem cells to osteoblasts and medium for the differentiation thereof
US9206394B2 (en) 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
ES2434256T3 (en) * 2010-05-28 2013-12-16 F. Hoffmann-La Roche Ag Method of culturing individual B cells and production of specific antibodies
JP6164746B2 (en) * 2012-05-22 2017-07-19 国立大学法人 東京大学 Method for producing antigen-specific T cells
CN103013914B (en) * 2012-12-13 2014-12-03 吉林省拓华生物科技有限公司 Method for in-vitro culture of killer T cells
US10564150B2 (en) * 2012-12-28 2020-02-18 Cellestis Limited Cell mediated immune response assay
CN107789647B (en) * 2016-09-05 2021-02-02 上海赛伦生物技术股份有限公司 Method for inactivating virus in animal serum or plasma
US20210393758A1 (en) * 2018-10-26 2021-12-23 Istituto Oncologico Veneto Iov-Irccs Hyaluronic acid as a natural adjuvant for protein and peptide-based vaccines
CN113416700B (en) * 2021-07-09 2023-04-11 天晴干细胞股份有限公司 Efficient factor-secreting NK cell amplification method and application thereof
WO2023085351A1 (en) * 2021-11-11 2023-05-19 株式会社デンソー T-cell differentiation regulating agent and composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2561131B2 (en) * 1988-06-30 1996-12-04 寳酒造株式会社 Cell adhesion activity polypeptide
US5198423A (en) * 1989-05-26 1993-03-30 Takara Shuzo Co., Ltd. Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
US5188959A (en) * 1989-09-28 1993-02-23 Trustees Of Tufts College Extracellular matrix protein adherent t cells
US6821778B1 (en) * 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
DE4412794A1 (en) * 1994-04-14 1995-12-14 Univ Ludwigs Albert Process for producing dendritic cells, cells thus obtained and containers for carrying out this process
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6692964B1 (en) * 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) * 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
WO1996034970A1 (en) * 1995-05-04 1996-11-07 United States Of America, Represented By The Secretary Of The Navy Improved methods for transfecting t cells
US6734014B1 (en) * 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
DE69739951D1 (en) * 1996-03-04 2010-09-16 Calyx Bio Ventures Inc MODIFIED QUICK-REINFORCEMENT METHOD ('MODIFIED-REM') FOR THE IN VITRO REPRODUCTION OF T-LYMPHOCYTES
CA2247131A1 (en) * 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
JP2001501085A (en) * 1996-09-23 2001-01-30 オントジニー インコーポレーテッド Hematopoietic stem cells and methods for producing such cells
WO1998033888A1 (en) * 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
US7816134B2 (en) * 2000-08-16 2010-10-19 Takara Bio Inc. Method of extensive culture of antigen-specific cytotoxic T cells
DE60232083D1 (en) * 2001-08-15 2009-06-04 Takara Bio Inc EXPANSION CULTURE PROCEDURE FOR ANTIGEN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES

Also Published As

Publication number Publication date
US20040115809A1 (en) 2004-06-17
EP1312670A4 (en) 2005-11-30
US7816134B2 (en) 2010-10-19
KR20030062317A (en) 2003-07-23
JP4231688B2 (en) 2009-03-04
CN1222612C (en) 2005-10-12
EP1312670A1 (en) 2003-05-21
WO2002014481A1 (en) 2002-02-21
TWI235764B (en) 2005-07-11
KR100715926B1 (en) 2007-05-08
US20080166325A1 (en) 2008-07-10
CN1469923A (en) 2004-01-21

Similar Documents

Publication Publication Date Title
AU2001278734A1 (en) Method of extensive culture of antigen-specific cytotoxic t cells
AU2001294520A1 (en) Methods and compositions for increasing protein yield from a cell culture
AU2002319780A1 (en) Alternative compositions and methods for the culture of stem cells
AU2001286202A1 (en) Method of culturing mesenchymal stem cells
AU5090200A (en) Culture chamber
AU2002230527A1 (en) Mailer for cell culture apparatus
AU1236801A (en) Activation of hcv-specific t cells
AU2001271502A1 (en) Methods and compositions for isolating biologically active antibodies
AU2001250036A1 (en) Microdroplet cell culture technique
AU2001235452A1 (en) Cell culture media
AU5632600A (en) Methods of making pancreatic islet cells
AU2002336930A1 (en) Method for producing isolated cell cultures, culture medium for cultivating cell cultures and cell culture
AU2001262697A1 (en) Method of amplifying natural killer t cells
AU2001233502A1 (en) Pancreatic islet cell growth factors
AU2002235728A1 (en) Method for generating insulin-secreting cells suitable for transplantation
AU2001227175A1 (en) Method for thermal transformation of biomass
AU2001246949A1 (en) Process of culturing algae
AU2002309330A1 (en) Isolation method of mesenchymal cells
AU2001236718A1 (en) Bioreactor and related method
AU2001275897A1 (en) Improvement of cell culture performance
AU2001290321A1 (en) Method of producing fuel cell
AU4771600A (en) Cells, culture methods and their uses
GB9904773D0 (en) Culture of mycobacteria
AU1057901A (en) Method of preparing cell fraction containing hemangioblasts
AU1720501A (en) Methods of producing novel enzymes